cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2022-3487cardiovascular-3487Research ArticleСОВЕТ ЭКСПЕРТОВEXPERT CONSENSUSРезолюция Cовета экспертов по актуальным вопросам применения ацетилсалициловой кислоты с целью первичной профилактики сердечно-сосудистых заболеваний в свете новых научных данных и обновленных клинических рекомендацийThe resolution of the Expert Council on current issues of the use of acetylsalicylic acid for the purpose of primary prevention of cardiovascular diseases in the light of new scientific data and updated clinical guidelineshttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Оксана Михайловна Драпкина — академик РАН, профессор, президент Российского общества профилактики неинфекционных заболеваний, директор ФГБУ "НМИЦ ТПМ" Минздрава России, главный внештатный специалист по терапии и общей врачебной практике Минздрава России.

Москва

drapkina@bk.ruhttps://orcid.org/0000-0001-8537-3639ВавиловаТ. В.VavilovaT. V.

Татьяна Владимировна Вавилова — профессор, заслуженный деятель науки РФ, заведующий кафедрой лабораторной медицины и генетики ФГБУ "НМИЦ им. В. А. Алмазова" Минздрава России, главный внештатный специалист по клинической лабораторной диагностике Минздрава России.

Санкт-Петербург

vtv.lab.spb@gmail.comhttps://orcid.org/0000-0003-1480-0458КарповЮ. А.KarpovYu. A.

Юрий Александрович Карпов — профессор, руководитель отдела ангиологии.

Москва

yuri_karpov@inbox.ruhttps://orcid.org/0000-0002-5873-1768КобалаваЖ. Д.KobalavaZh. D.

Жанна Давидовна Кобалава — член-корреспондент РАН, профессор, заслуженный деятель науки Российской Федерации, вице-президент Российского общества профилактики неинфекционных заболеваний, заведующий кафедрой внутренних болезней с курсом кардиологии и функциональной диагностики им. акад. В. С. Моисеева.

Москва

zkobalava@mail.ruhttps://orcid.org/0000-0001-8830-7231ЛомакинН. В.LomakinN. V.

Никита Валерьевич Ломакин — доктор медицинских наук, руководитель отделения неотложной кардиологии с блоком кардиореанимации ФГБУ "ЦКБ с поликлиникой" Управления делами Президента Российской Федерации, главный внештатный специалист кардиолог Управления делами Президента Российской Федерации.

Москва

lomakinnikita@gmail.comhttps://orcid.org/0000-0002-0783-488XМартыновА. И.MartynovА. I.

Анатолий Иванович Мартынов — академик РАН, профессор, заведующий кафедрой внутренних болезней № 1 лечебного факультета с курсом эхокардиографии ФПО ФГБОУ ВО МГМСУ им. А. И. Евдокимова Минздрава России, президент Российского научного медицинского общества терапевтов.

Москва

idjema@gmail.comhttps://orcid.org/0000-0002-3015-9317РойтманЕ. В.RoitmanE. V.

Евгений Витальевич Ройтман — профессор кафедры онкологии, гематологии и лучевой терапии ФГАОУ ВО "РНИМУ им. Н.И. Пирогова" Минздрава России, президент Национальной ассоциации специалистов по тромбозам, клинической гемостазиологии и гемореологии.

Москва

roitman@hemostas.ruhttps://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Дмитрий Алексеевич Сычёв — академик РАН, профессор, профессор РАН, ректор.

Москва

rodinda@rmapo.ruФГБУ НМИЦ ТПМ, Минздрав РоссииРоссияФГБУ НМИЦ им. В.А. Алмазова, Минздрав РоссииРоссияФГБУ НМИЦ кардиологии им. Е.А. Чазова, Минздрав РоссииРоссияФГАОУ ВО РУДН, медицинский институтРоссияФГБУ ЦКБ с поликлиникой Управления делами Президента Российской ФедерацииРоссияФПО ФГБОУ ВО МГМСУ им. А.И. Евдокимова, Минздрав РоссииРоссияФГАОУ ВО РНИМУ им. Н.И. Пирогова, Минздрав РоссииРоссияФГБОУ ДПО РМАНПО, Минздрав РоссииРоссия202217012023211234873487Copyright © Драпкина О.М., Вавилова Т.В., Карпов Ю.А., Кобалава Ж.Д., Ломакин Н.В., Мартынов А.И., Ройтман Е.В., Сычёв Д.А., 20232023Драпкина О.М., Вавилова Т.В., Карпов Ю.А., Кобалава Ж.Д., Ломакин Н.В., Мартынов А.И., Ройтман Е.В., Сычёв Д.А.Drapkina O.M., Vavilova T.V., Karpov Y.A., Kobalava Z.D., Lomakin N.V., Martynov А.I., Roitman E.V., Sychev D.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3487Эксперты

Эксперты: Драпкина О. М., Вавилова Т. В., Карпов Ю. А., Кобалава Ж. Д., Ломакин Н. В., Мартынов А. И., Ройтман Е. В., Сычев Д. А.

Научные сообщества

Научные сообщества: Российское общество профилактики неинфекционных заболеваний (РОПНИЗ), Российское научное медицинское общество терапевтов (РНМОТ), Российский антитромботический форум (РАФ), Национальная ассоциация  по тромбозу и гемостазу (НАТГ).

Expert Council: Drapkina O. M., Vavilova T. V., Karpov Yu. A., Kobalava Zh. D., Lomakin N. V., Martynov A. I., Roitman E. V., Sychev D. A.Scientific communities: the Russian Society for the Prevention of Non-Communicable Diseases (ROPNIZ), the Russian Scientific Medical Society of Therapists (RNMOT), the Russian Antithrombotic Forum (RAF), the National Association for Thrombosis and Hemostasis (NATH).

антиагрегантная терапияацетилсалициловая кислотапервичная профилактикастратификация рискасердечно-сосудистый рискпрогнозantiplatelet therapyacetylsalicylic acidprimary preventionrisk stratificationcardiovascular riskprognosisЭкспертный совет проведен при поддержке АО "Нижфарм" (группа компаний STADA)The Expert Council was held with the support of JSC "Nizhpharm" (STADA Group of companies)ReferencesРоссийский статистический ежегодник. 2021/Федеральная служба государственной статистики (Росстат). М., 2021; с. 224.Russian Statistical Yearbook. 2021/Federal State Statistics Service (Rosstat). Moscow, 2021; p. 224 (In Russ.)Национальные рекомендации Всероссийского научного общества кардиологов по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011;10(6S2):2-64. EDN VZPAUN.National guidelines for the All-Russian Scientific Society for Cardiovascular Prevention. Cardiovascular Therapy and Prevention. 2011;10(6S2):2-64. (In Russ.) EDN VZPAUN.Оганов Р. Г., Герасименко Н. Ф., Погосова Г. В. и др. Профилактика сердечно-сосудистых заболеваний: пути развития. Кардиоваскулярная терапия и профилактика. 2011;10(3):5-7. doi:10.15829/1728-8800-2011-3-5-7.Oganov RG, Gerasimenko NF, Pogosova GV, et al. Prevention of cardiovascular disease: the development. Cardiovascular Therapy and Prevention. 2011;10(3):5-7. (In Russ.) doi:10.15829/1728-8800-2011-3-5-7.Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. doi:10.1093/eurheartj/ehab484.Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. doi:10.1093/eurheartj/ehab484.Чулков В. С., Гаврилова Е. С., Чулков В. С., Панкова Е. Д., Ленец Е. А., Ткаченко П. Е. Первичная профилактика сердечно-сосудистых заболеваний: акцент на коррекцию поведенческих факторов риска. Российский кардиологический журнал. 2021;26(3S):4278 doi:10.15829/1560-4071-2021-4278.Chulkov VS, Gavrilova ES, Chulkov VS, et al. Primary prevention of cardiovascular disease: focus on improving behavioral risk factors. Russian Journal of Cardiology. 2021;26(3S):4278. (In Russ.) doi:10.15829/1560-4071-2021-4278.Бойцов С. А., Погосова Н. В., Бубнова М. Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.Boytsov SA, Pogosova NV, Bubnova MG, et al. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.) doi:10.15829/1560-4071-2018-6-7-122.Драпкина О. М., Концевая А. В., Калинина А. М. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):3235. doi:10.15829/1728-8800-2022-3235.Drapkina OM, Kontsevaya AV, Kalinina AM, et al. Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) doi:10.15829/1728-8800-2022-3235.Murphy E, Curneen JMG, McEvoy JW. Aspirin in the modern era of cardiovascular disease prevention. Methodist DeBakey Cardiovascular J. 2021;17(4):36-47. doi:10.14797/mdcvj.293.Murphy E, Curneen JMG, McEvoy JW. Aspirin in the modern era of cardiovascular disease prevention. Methodist DeBakey Cardiovascular J. 2021;17(4):36-47. doi:10.14797/mdcvj.293.Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62. doi:10.1016/s0140-6736(98)04311-6.Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62. doi:10.1016/s0140-6736(98)04311-6.Landolfi R, Marchioli R. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial. Semin Thromb Hemost. 1997;23(5):473-8. doi:10.1055/s-2007-996124.Landolfi R, Marchioli R. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial. Semin Thromb Hemost. 1997;23(5):473-8. doi:10.1055/s-2007-996124.Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007; 261(3):276-84. doi:10.1111/j.1365-2796.2006.01763.x.Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007; 261(3):276-84. doi:10.1111/j.1365-2796.2006.01763.x.Blankstein R, Chandrashekhar Y. Extensive Coronary Artery Calcifications: No Longer Primary Prevention! J Am Coll Cardiol Img. 2020;13:183-5. doi:10.1016/j.jcmg.2019.12.007.Blankstein R, Chandrashekhar Y. Extensive Coronary Artery Calcifications: No Longer Primary Prevention! J Am Coll Cardiol Img. 2020;13:183-5. doi:10.1016/j.jcmg.2019.12.007.Aimo A, De Caterina R. Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. Pol Arch Intern Med. 2020;130(2):121-9. doi:10.20452/pamw.15215.Aimo A, De Caterina R. Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. Pol Arch Intern Med. 2020;130(2):121-9. doi:10.20452/pamw.15215.Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/ AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-143. doi:10.1161/CIR.0000000000000625.Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/ AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/ PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082-143. doi:10.1161/CIR.0000000000000625.Chulkov VS, Lenets EA, Chulkov VlS, et al. Gender characteristics of the pathogenesis, prevention and treatment of metabolic syndrome. Arterial Hypertension. 2020;26(4):371-82. doi:10.18705/1607-419X-2020-26-4-371-382.Chulkov VS, Lenets EA, Chulkov VlS, et al. Gender characteristics of the pathogenesis, prevention and treatment of metabolic syndrome. Arterial Hypertension. 2020;26(4):371-82. doi:10.18705/1607-419X-2020-26-4-371-382.Calderone D, Greco A, Ingala S, et al. Efficacy and safety of aspirin for primary cardiovascular risk prevention in younger and older age: an updated systematic review and meta-analysis of 173,810 subjects from 21 randomized studies. Thromb Haemost. 2022;122(3):445-55. doi:10.1055/a-1667-7427.Calderone D, Greco A, Ingala S, et al. Efficacy and safety of aspirin for primary cardiovascular risk prevention in younger and older age: an updated systematic review and meta-analysis of 173,810 subjects from 21 randomized studies. Thromb Haemost. 2022;122(3):445-55. doi:10.1055/a-1667-7427.Zhao B, Wu Q, Wang L, et al. Pros and cons of aspirin for the primary prevention of cardiovascular events: a secondary study of trial sequential analysis. Front Pharmacol. 2020;11:592116. doi:10.3389/fphar.2020.592116.Zhao B, Wu Q, Wang L, et al. Pros and cons of aspirin for the primary prevention of cardiovascular events: a secondary study of trial sequential analysis. Front Pharmacol. 2020;11:592116. doi:10.3389/fphar.2020.592116.Masson G, Lobo M, Masson W, et al. Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk. Arch Cardiol Mex. 2020;90(3):293-9. doi:10.24875/ACM.20000267.Masson G, Lobo M, Masson W, et al. Aspirin in primary prevention. Meta-analysis stratified by baseline cardiovascular risk. Arch Cardiol Mex. 2020;90(3):293-9. doi:10.24875/ACM.20000267.Bowman L, Mafham M, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379(16):1529-39. doi:10.1056/NEJMoa1804988.Bowman L, Mafham M, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379(16):1529-39. doi:10.1056/NEJMoa1804988.Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet. 2018;392(10152):1036-46. doi:10.1016/S0140-6736(18)31924-X.Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet. 2018;392(10152):1036-46. doi:10.1016/S0140-6736(18)31924-X.Aimo A, De Caterina R. Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. Anatol J Cardiol. 2020;23(2):70-8. doi:10.14744/AnatolJCardiol.2019.89916.Aimo A, De Caterina R. Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification. Anatol J Cardiol. 2020;23(2):70-8. doi:10.14744/AnatolJCardiol.2019.89916.McNeil JJ, Nelson MR, Woods RL, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018;379(16):1519-28. doi:10.1056/NEJMoa1803955.McNeil JJ, Nelson MR, Woods RL, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018;379(16):1519-28. doi:10.1056/NEJMoa1803955.Gelbenegger G, Postula M, Pecen L, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med. 2019;17(1):198. doi:10.1186/s12916-019-1428-0.Gelbenegger G, Postula M, Pecen L, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med. 2019;17(1):198. doi:10.1186/s12916-019-1428-0.Ma H, Gu Q, Niu H, et al. Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:741374. doi:10.3389/fendo.2021.741374.Ma H, Gu Q, Niu H, et al. Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:741374. doi:10.3389/fendo.2021.741374.Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol. 2019;18(1):70. doi:10.1186/s12933-019-0875-4.Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol. 2019;18(1):70. doi:10.1186/s12933-019-0875-4.Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for Primary Prevention of Cardiovascular Events. J Am Coll Cardiol. 2019;73(23):2915-29. doi:10.1016/j.jacc.2019.03.501.Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for Primary Prevention of Cardiovascular Events. J Am Coll Cardiol. 2019;73(23):2915-29. doi:10.1016/j.jacc.2019.03.501.Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data metaanalysis. Lancet. 2021;398(10306):1133-46. doi:10.1016/S01406736(21)01827-4.Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data metaanalysis. Lancet. 2021;398(10306):1133-46. doi:10.1016/S01406736(21)01827-4.Sundström J, Hedberg J, Thuresson M, et al. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study. Circulation. 2017;136(13):1183-92. doi:10.1161/CIRCULATIONAHA.117.028321.Sundström J, Hedberg J, Thuresson M, et al. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study. Circulation. 2017;136(13):1183-92. doi:10.1161/CIRCULATIONAHA.117.028321.Gitin A, Pfeffer MA, DeMets DL, Hennekens CH. Aspirin in Primary Prevention: Needs Individual Clinical Judgments. Am J Med. 2020;133(7):774-6. doi:10.1016/j.amjmed.2020.01.006.Gitin A, Pfeffer MA, DeMets DL, Hennekens CH. Aspirin in Primary Prevention: Needs Individual Clinical Judgments. Am J Med. 2020;133(7):774-6. doi:10.1016/j.amjmed.2020.01.006.Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486.Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486.Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. doi:10.1093/eurheartj/ehaa575.Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. doi:10.1093/eurheartj/ehaa575.Барбараш О. Л., Дупляков Д. В., Затейщиков Д. А. и др. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(4):4449. doi:10.15829/1560-4071-2021-4449.Barbarash OL, Duplyakov DV, Zateischikov DA, et al. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardiology. 2021;26(4):4449. (In Russ.) doi:10.15829/1560-4071-2021-4449.Акчурин Р. С., Алекян Б. Г., Аронов Д. М. и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/29/1560-4071-2020-4076.Akchurin RS, Alekyan BG, Aronov DM, et al. 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.) doi:10.15829/29/1560-4071-2020-4076.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-646. doi:10.1161/CIR.0000000000000678. Correction: Circulation. 2020;141(16):e774.Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596-646. doi:10.1161/CIR.0000000000000678. Correction: Circulation. 2020;141(16):e774.Davidson KW, Barry MJ, Mangione CM, et al. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(16):157784. doi:10.1001/jama.2022.4983.Davidson KW, Barry MJ, Mangione CM, et al. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(16):157784. doi:10.1001/jama.2022.4983.Li XY, Shi ZW, Zhao D, et al. 2019 Chinese expert consensus statement on aspirin application in primary prevention of cardiovascular disease. Chin Med J (Engl). 2020;133(10):1221-3. doi:10.1097/CM9.0000000000000762.Li XY, Shi ZW, Zhao D, et al. 2019 Chinese expert consensus statement on aspirin application in primary prevention of cardiovascular disease. Chin Med J (Engl). 2020;133(10):1221-3. doi:10.1097/CM9.0000000000000762.De Caterina R, Aimo A, Ridker PM. Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review. Thromb Haemost. 2020 Feb;120(2):199-206. doi:10.1055/s-0039-3400294.De Caterina R, Aimo A, Ridker PM. Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Risk-A Review. Thromb Haemost. 2020 Feb;120(2):199-206. doi:10.1055/s-0039-3400294.Jhaveri A, Sibley RA, Spatz ES, et al. Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty. Curr Cardiol Rep. 2021;23(6):67. doi:10.1007/s11886-021-01499-y.Jhaveri A, Sibley RA, Spatz ES, et al. Aspirin, Statins, and Primary Prevention: Opportunities for Shared Decision Making in the Face of Uncertainty. Curr Cardiol Rep. 2021;23(6):67. doi:10.1007/s11886-021-01499-y.Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425.Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. doi:10.1093/eurheartj/ehz425.Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095.Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095.Cainzos-Achirica M, Miedema MD, McEvoy JW, et al. Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). Circulation. 2020;141(19):1541-53. doi:10.1161/CIRCULATIONAHA.119.045010.Cainzos-Achirica M, Miedema MD, McEvoy JW, et al. Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). Circulation. 2020;141(19):1541-53. doi:10.1161/CIRCULATIONAHA.119.045010.Miedema MD, Duprez DA, Misialek JR, et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes. 2014;7(3):453-60. doi:10.1161/CIRCOUTCOMES.113.000690.Miedema MD, Duprez DA, Misialek JR, et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes. 2014;7(3):453-60. doi:10.1161/CIRCOUTCOMES.113.000690.Schenone AL, Lincoff AM. Aspirin for primary prevention of atherosclerotic cardiovascular events. Cleve Clin J Med. 2020;87(5):300-11. doi:10.3949/ccjm.87a.19045.Schenone AL, Lincoff AM. Aspirin for primary prevention of atherosclerotic cardiovascular events. Cleve Clin J Med. 2020;87(5):300-11. doi:10.3949/ccjm.87a.19045.Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009; 203(2):371-6. doi:10.1016/j.atherosclerosis.2008.07.019.Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009; 203(2):371-6. doi:10.1016/j.atherosclerosis.2008.07.019.Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231-41. doi:10.1016/S2468-1253(18)30037-2.Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231-41. doi:10.1016/S2468-1253(18)30037-2.Parish S, Mafham M, Offer A, et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. Eur Heart J. 2022;43(21):2010-9. doi:10.1093/eurheartj/ehac179.Parish S, Mafham M, Offer A, et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. Eur Heart J. 2022;43(21):2010-9. doi:10.1093/eurheartj/ehac179.Mo C, Sun G, Lu ML, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol. 2015;21(17):5382-92. doi:10.3748/wjg.v21.i17.5382.Mo C, Sun G, Lu ML, et al. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol. 2015;21(17):5382-92. doi:10.3748/wjg.v21.i17.5382.García Rodríguez LA, Lanas A, Soriano-Gabarró M, et al. Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. J Clin Med. 2020;9(4):928. doi:10.3390/jcm9040928.García Rodríguez LA, Lanas A, Soriano-Gabarró M, et al. Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. J Clin Med. 2020;9(4):928. doi:10.3390/jcm9040928.Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37(8):2153-8. doi:10.1161/01.STR.0000231683.43347.ec.Cox D, Maree AO, Dooley M, et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37(8):2153-8. doi:10.1161/01.STR.0000231683.43347.ec.Bhatt DL, Grosser T, Dong JF, et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017;69(6):603-12. doi:10.1016/j.jacc.2016.11.050.Bhatt DL, Grosser T, Dong JF, et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017;69(6):603-12. doi:10.1016/j.jacc.2016.11.050.Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672f-86. doi:10.1093/eurheartj/ehy066.Rocca B, Fox KAA, Ajjan RA, et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672f-86. doi:10.1093/eurheartj/ehy066.de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1. doi:10.1186/1472-6904-1-1.de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1. doi:10.1186/1472-6904-1-1.Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirinassociated major upper-gastrointestinal bleeding with entericcoated or buffered product. Lancet. 1996;348(9039):1413-6. doi:10.1016/S0140-6736(96)01254-8.Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirinassociated major upper-gastrointestinal bleeding with entericcoated or buffered product. Lancet. 1996;348(9039):1413-6. doi:10.1016/S0140-6736(96)01254-8.Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297(18):2018-24. doi:10.1001/jama.297.18.2018.Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297(18):2018-24. doi:10.1001/jama.297.18.2018.Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95(10):1218-22. doi:10.1016/j.amjcard.2005.01.049.Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95(10):1218-22. doi:10.1016/j.amjcard.2005.01.049.Serebruany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75(1):40-7. doi:10.1002/ajh.10451.Serebruany VL, Malinin AI, Eisert RM, et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75(1):40-7. doi:10.1002/ajh.10451.Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13:374-92. doi:10.1016/j.jacl.2019.04.010.Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13:374-92. doi:10.1016/j.jacl.2019.04.010.Abrignani MG, Gatta L, Gabrielli D, et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med. 2021;85:1-13. doi:10.1016/j.ejim.2020.11.014.Abrignani MG, Gatta L, Gabrielli D, et al. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med. 2021;85:1-13. doi:10.1016/j.ejim.2020.11.014.Лазебник Л. Б., Голованова Е. В., Алексеенко С. А. и др. Рекомендации по профилактике и лечению эзофаго-гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами (НПВП). Экспериментальная и клиническая гастроэнтерология. 2018;151(3):4-18.Lazebnik LB, Golovanova EV, Alekseenko SA, et al. Recommendations for the prevention and treatment of esophago-gastroentero-colopathy induced by nonsteroidal anti-inflammatory drugs (NSAIDs). Experimental and Clinical Gastroenterology. 2018;(3):4-18. (In Russ.)

The authors declare that there are no conflicts of interest present.